홈 > 시장보고서 > 의약품 > 파이프라인 분석

시장보고서

상품코드

2128971

혈액 질환 시장 : 진단 검사별, 치료법별, 질환 유형별, 질환 카테고리별, 국가별, 지역별 - 업계 분석, 시장 규모, 시장 점유율 및 예측(2026-2033년)

Hematological Disorders Market, By Diagnostic Test, By Therapeutic Approach, By Disease Type, By Disease Category, By Country, and By Region -Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033

발행일: 2026년 09월 | 리서치사: 구분자

AnalystView Market Insights | 페이지 정보: 영문 401 Pages | 배송안내 : 2-3일 (영업일 기준)

가격

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 3,250

￦ 4,531,000

PDF (5 User License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,560

￦ 6,358,000

PDF & Excel (Enterprise User License)

PDF & Excel 보고서를 동일 기업 내 모든 사용자가 사용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,650

￦ 7,877,000

※ 부가세 별도

한글목차

영문목차

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

혈액 질환 시장 규모는 2025년에 1,387억 50만 달러로 평가되었고, 2026-2033년 CAGR 8.2%로 성장할 전망입니다.

혈액 질환에는 혈액 세포, 골수, 림프 조직 및 관련 면역계에서 발생하는 악성 및 비악성 질환이 포함됩니다. 상업 분야에서는 진단과 치료가 임상 검사 진단과 고도로 전문화된 치료 영역의 결합을 통해 이루어지고 있습니다. 진단 부문에는 일상적인 혈액 검사 외에도 유세포 분석, 면역 조직 화학, 분자 검사, 세포유전학적 검사 및 골수 검사가 포함되며, 이를 통해 질환, 그 아형, 예후 및 잔류 병변의 상태를 진단합니다. 이에 상응하는 치료 분야에는 표적 치료, 화학요법, 이식, 방사선 치료 및 면역 요법이 포함됩니다. 이러한 전문성의 정도는 EBMT 등록부에서 엿볼 수 있습니다. 이 레지스트리에는 2025년에 3만 7,329건의 신규 사례가 등록되어 있으며, 그중 1만 8,875건이 동종 조혈모세포 이식(HCT), 1만 8,504건이 자가 조혈모세포 이식(HCT)이었습니다. 이에 따라 시장은 개별 제품이 아닌, 진단에서 치료에 이르는 일련의 과정으로 통합이 점점 더 진행되면서 이에 중점을 두게 되었습니다.

혈액 질환 시장 : 시장 역학

분자 수준에서 정의되고 치료 반응성을 고려한 질환 분류의 확대

표적 치료는 혈액 질환 진단과 관련하여 임상의들이 갖는 요구를 재정의하고 있습니다. 치료법 선택에 있어 분자 수준의 변화, 면역 표현형 및 치료 적격성이 중요한 역할을 하는 경우, 질병 자체를 특정하는 것만으로는 더 이상 충분하지 않습니다. 이는 형태학, 유세포 분석, 세포유전학 및 분자 검사를 포함한 진단이 이루어지는 림프종 및 백혈병의 치료 경로에서 특히 두드러집니다. 2025년, FDA는 598명의 환자를 대상으로 한 ECHO 임상시험 결과를 바탕으로, 새로 진단된 맨틀세포 림프종에 대한 아카라부티닙의 기존 승인에 더해, 해당 약물의 치료 적응증 확대도 승인했습니다. 이러한 규제는 질환 분류와 표적 치료 간의 연관성을 강조하는 것입니다. 따라서 진단 검사 기관은 표적 치료를 원활하게 진행하기 위해 질환에 관한 시기적절하고 표준화되며 실용적인 정보를 제공해야 한다는 압박을 점점 더 강하게 받고 있습니다.

혈액 질환 시장 : 시장 세분화 분석

세계 혈액 질환 시장은 진단 검사, 치료 접근법, 질환 유형, 질환 범주 및 지역을 기준으로 세분화되어 있습니다.

진단 검사별로 살펴보면, 진단 검사의 구조는 대체 가능한 검사라기보다는 혈액병리학적 검사의 계층 구조를 따릅니다. 전혈구계수(CBC)는 혈액 세포의 이상을 정량적으로 평가하고, 골수 천자 및 생검은 세포 및 조직 구조에 대한 증거를 제공하며, 유세포분석은 다중 매개변수 면역 표현형 분석을 가능하게 합니다. 면역조직화학은 조직상의 마커 패턴을 밝혀내고, 분자진단 및 세포유전학은 유전적 및 염색체 이상 식별에 도움이 됩니다. 기술적 차별화는 유세포 분석에서 두드러지며, 벡만 콜터(Beckman Coulter)사의 ‘2025 CytoFLEX 모자이크 모듈’은 88개의 검출 채널을 구현하고 있습니다. 이는 업계가 고차원 평가로 전환되고 있음을 보여줍니다. 따라서 앞서 언급한 세분화의 상업적 중요성은 진단 심도의 상호 보완성에서 비롯됩니다.

치료 접근 방식의 관점에서 볼 때, 치료 전략은 단순한 치료법의 계층 구조가 아니라 질병의 생물학적 특성, 환자의 적격성, 병기, 과거 치료 이력 및 반응의 지속성에 따라 결정됩니다. 화학요법과 방사선 요법은 확립된 치료 경로의 일부이지만, 분자 표적 요법과 면역 요법에서는 분자 및 면역적 특성을 점점 더 많이 활용하고 있습니다. 적절하게 선별된 환자의 경우, 조혈모세포 이식이 여전히 집중적인 치료 옵션으로 남아 있지만, 질환 특유의 요구 사항이나 지지 요법의 필요성에 대해서는 다른 접근법도 이용할 수 있습니다. 이러한 변화는 2025년 규제 관련 증거에도 반영되어 있습니다. 재발성 또는 난치성 여포성 림프종에 대한 타파시타맙과 레날리도마이드, 리툭시맙의 병용 요법에 대한 FDA 승인은 548명의 환자를 대상으로 한 inMIND 임상시험에 기반한 것으로, 이는 면역요법의 병용이 단독 치료법이 아닌 치료 전략에 통합되고 있음을 보여줍니다. 따라서 치료 세분화는 점점 더 개인화된 치료 순서를 반영하는 방향으로 변화하고 있습니다.

혈액 질환 시장 : 지역별 인사이트

유럽에서는 확립된 이식, 등록부, 전문 의료 센터로 구성된 생태계에 의해 혈액 질환 치료가 뒷받침되고 있습니다. EBMT의 2025년 등록부에는 1만 8,875건의 동종 조혈모세포 이식, 1만 8,504건의 자가 이식,4,757건의 CAR-T 요법이 기록되어 있으며, 이는 이 지역의 전체 임상 네트워크에 걸쳐 첨단 세포 치료 인프라가 널리 보급되어 있음을 보여줍니다. 또한, 이 생태계에서는 진단 모니터링의 필요성도 대두되고 있습니다. 이는 이식 및 세포 치료에서 치료 전 질환의 특성 평가와 치료 후 경과 관찰이 필수적이기 때문입니다. EBMT는 2025년 10월, 해당 레지스트리를 통해 ISO/IEC 27001:2022 인증을 획득함으로써, 임상 데이터 환경의 중요성이 점점 더 커지고 있음을 보여주었습니다. 따라서 유럽은 진단, 이식, 세포 치료, 그리고 임상 데이터 인프라가 서로 점점 더 밀접하게 연결되어 있는 상호 연결된 시장이라고 할 수 있습니다.

아시아는 혈액 질환의 부담이 크고 전문 치료 인프라가 확대됨에 따라 중요한 시장으로 부상하고 있으며, 중국은 첨단 세포 치료 분야에서 중요한 역할을 하고 있습니다. 2025년 중국 전문가들의 합의에 따르면, 악성 종양의 진단, 분류, 치료, 모니터링에서 유세포 분석법의 역할이 강조되고 있습니다. 이 지역에서는 치료 인프라 구축도 진행되고 있으며, 상하이 SinoUnited 병원은 2025년 5월 21일, 혈액암 및 해외 환자를 대상으로 한 국제적인 CAR-T 세포 치료 센터를 개설했습니다. 이러한 동향은 아시아 시장이 혈액학 분야의 서비스에 그치지 않고 전문적인 분자 치료, 세포 치료, 면역 치료 분야로 확대되고 있으며, 복잡한 혈액 질환에 필요한 진단 및 치료 인프라가 확충되고 있음을 보여줍니다.

Hematological diseases include malignant and non-malignant diseases of blood cells, bone marrow, lymphoid tissues, and associated immune systems; in the commercial space, the diagnosis and treatment are a combination of laboratory diagnostics and very specialized therapeutic areas. The diagnostics segment encompasses routine hematology along with flow cytometry, immunohistochemistry, molecular tests, cytogenetic tests, and bone marrow studies to diagnose diseases, their subtypes, prognosis, and residual disease status. The corresponding therapy segment includes targeted drugs, chemotherapy, transplantation, radiotherapy, and immunotherapy. The extent of specialty can be seen in the EBMT Registry, which registered 37,329 new cases in 2025, comprising 18,875 allogeneic HCTs and 18,504 autologous HCTs. This positions the market around increasingly integrated diagnosis-to-treatment pathways rather than isolated products.

Hematological Disorders Market- Market Dynamics

Expansion of Molecularly Defined and Treatment-Responsive Disease Classification

Targeted therapies are redefining the needs that clinicians have regarding hematological diagnostics: the sole identification of the disease itself is no longer sufficient in cases where molecular changes, immunophenotype, and eligibility for treatment play an important role in the choice of treatment method. This is especially noticeable in the treatment pathways for lymphomas and leukemias, where diagnostics include morphology, flow cytometry, cytogenetics, and molecular tests. In 2025, the FDA granted traditional approval for acalabrutinib in newly diagnosed mantle cell lymphoma based on results from the 598 patients' ECHO trial, as well as an expanded treatment indication for acalabrutinib. These types of regulations emphasize the link between disease classification and targeted treatment. Diagnostic labs are thus under increasing pressure to provide timely, standardized, and actionable information about diseases in order to facilitate targeted treatment.

Hematological Disorders Market- Segmentation Analysis:

The Global Hematological Disorders Market is segmented on the basis of Diagnostic Test, Therapeutic Approach, Disease Type, Disease Category, and Region.

By diagnostic test, the test structure for diagnostic tests follows a hierarchy of hematopathology tests rather than tests that could be substituted. Complete blood counts provide a quantitative assessment of blood cell disorders, while bone marrow aspiration and biopsy give cellular and architectural proof, and flow cytometry offers multi-parameter immunophenotyping. Immunohistochemistry reveals marker patterns on tissues, while molecular diagnostics and cytogenetics help identify genetic and chromosomal disorders. The technology differentiation is evident in flow cytometry, in which the 2025 CytoFLEX mosaic module by Beckman Coulter enables 88 detection channels. This demonstrates how the industry is shifting towards high-dimensional assessment. The commercial importance of the above segmentation, therefore, arises from the complementary diagnostic depth.

By therapeutic approach, the therapeutic strategy is dictated by disease biology, patient eligibility, disease stage, prior treatment exposure, and response durability, rather than by a simple hierarchy of therapies. Chemotherapy and radiation are part of established treatment pathways, while targeted therapy and immunotherapy increasingly take advantage of molecular or immune features. Stem cell transplantation remains an intensive option for appropriately selected patients, while other approaches are available for disease-specific or supportive needs. The change is reflected in 2025 regulatory evidence: FDA approval of tafasitamab with lenalidomide and rituximab for relapsed or refractory follicular lymphoma was based on the inMIND trial with 548 patients, demonstrating the integration of combination immunotherapy into treatment strategies, rather than as a stand-alone modality. Thus, therapeutic segmentation increasingly reflects individualized treatment sequencing.

Hematological Disorders Market- Geographical Insights

Europe occupies a position where hematological treatment is supported by a well-established transplantation, registry, and specialist-center ecosystem. The EBMT's 2025 registry recorded 18,875 allogeneic hematopoietic cell transplants and 18,504 autologous transplants alongside 4,757 CAR T procedures, showing the wide reach of advanced cellular treatment infrastructure across the region's clinical network. This ecosystem also creates a need for diagnostic monitoring because transplantation and cellular therapies require disease characterization before treatment and monitoring afterward. EBMT achieved ISO/IEC 27001:2022 certification for its registry in October 2025, demonstrating the growing importance of clinical data environments. Europe, therefore, represents a connected market where diagnostics, transplantation, cellular therapy, and clinical data infrastructure increasingly overlap.

Asia is significant market due to burden of hematological diseases and expanding specialist treatment infrastructure, with China playing a key role in advanced cellular therapy. A 2025 Chinese expert consensus emphasizes flow cytometry's role in diagnosing, classifying, treating, and monitoring malignancies. The region is also building treatment infrastructure: Shanghai SinoUnited Hospital opened an international CAR T cell therapy center on May 21, 2025, aimed at hematological cancers and patients from other countries. These developments show that Asian markets are moving beyond hematology services toward specialized molecular, cellular, and immunotherapy capabilities, broadening the diagnostic and therapeutic infrastructure needed for complex blood disorders.

Hematological Disorders Market- Competitive Landscape:

Competition is now defined by the capacity to link deep diagnostic testing with clinical workflow processes rather than by the supply of single instrumentation or therapy. In diagnostics, firms such as Beckman Coulter, BD, Roche, Abbott, Thermo Fisher Scientific, and other specialized suppliers have been competing based on multiparametric testing, automation, reagent systems, molecular technologies, and laboratory integration. The launch of the CytoFLEX mosaic spectral module by Beckman Coulter by 2025, featuring ten autofluorescence channels along with an advanced detection system, shows how instrument manufacturers can differentiate themselves through complex sample handling and analysis. Therapies, drug firms, and biotechs are now competing in terms of specific inhibitors, antibody combinations, CAR-T therapy, and clinical data based on the condition being addressed. Thus, the competitive landscape is moving towards integrated precision care capabilities and clinically proven differentiation.

Recent Developments:

In December 2025, pirtobrutinib was FDA approved under the traditional route for treating CLL/SLL, which is relapsed or refractory post-covalent BTK inhibitor use. The study used for FDA approval was BRUIN-CLL-321, where the randomization of the patients was made for 238, and pirtobrutinib had a median PFS of 11.2 months.

In December 2025, lisocabtagene maraleucel (Breyanzi) was FDA approved for treating adults with relapsed or refractory marginal zone lymphoma post second-line systemic therapy. The efficacy analysis for FDA approval involved 77 patients who underwent leukapheresis and had an 84.4% response rate.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL HEMATOLOGICAL DISORDERS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Abbott Laboratories
Amgen Inc.
Sanofi
Baxter International Inc.
Bayer AG
Bristol Myers Squibb
F. Hoffmann-La Roche Ltd.
Biogen Inc.
Novartis AG
Pfizer Inc.
GSK plc
Johnson & Johnson
Takeda Pharmaceutical Company Limited
Sysmex Corporation
Siemens Healthineers
AstraZeneca
AbbVie Inc.
CSL Behring
Novo Nordisk A/S
Vertex Pharmaceuticals
Sobi
Others

GLOBALHEMATOLOGICAL DISORDERS MARKET, BY DIAGNOSTIC TEST- MARKET ANALYSIS, 2020 - 2033

Flow Cytometry
Complete Blood Count
Immunohistochemistry
Molecular Diagnostics
Bone Marrow Aspiration and Biopsy
Cytogenetics

GLOBAL HEMATOLOGICAL DISORDERS MARKET, BY THERAPEUTIC APPROACH- MARKET ANALYSIS, 2020 - 2033

Targeted Therapy
Chemotherapy
Stem Cell Transplant
Radiation Therapy
Immunotherapy
Others

GLOBAL HEMATOLOGICAL DISORDERS MARKET, BY DISEASE TYPE- MARKET ANALYSIS, 2020 - 2033

Leukemia
Lymphoma
Multiple Myeloma
Anemia
Hemophilia & Other Bleeding Disorders
Sickle Cell Disease & Other Hemoglobinopathies
Thrombosis & Other Coagulation Disorders
Myelodysplastic & Myeloproliferative Disorders
Others

GLOBAL HEMATOLOGICAL DISORDERS MARKET, BY DISEASE CATEGORY- MARKET ANALYSIS, 2020 - 2033

Malignant Hematological Disorders
Non-Malignant Hematological Disorders

GLOBAL HEMATOLOGICAL DISORDERS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Denmark
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Taiwan
Vietnam
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Iran
Qatar
Rest of MEA

1. Hematological Disorders Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
2.2. Competitive Insights

3. Hematological Disorders Key Market Trends

3.1. Hematological Disorders Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Hematological Disorders Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Hematological Disorders Market Opportunities
3.4. Hematological Disorders Market Future Trends

4. Hematological Disorders Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Hematological Disorders Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Hematological Disorders Market Landscape

6.1. Hematological Disorders Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Hematological Disorders Market - By Diagnostic Test

7.1. Overview
- 7.1.1. Segment Share Analysis, By Diagnostic Test, 2025 & 2033 (%)
- 7.1.2. Flow Cytometry
- 7.1.3. Complete Blood Count
- 7.1.4. Immunohistochemistry
- 7.1.5. Molecular Diagnostics
- 7.1.6. Bone Marrow Aspiration and Biopsy
- 7.1.7. Cytogenetics

8. Hematological Disorders Market - By Therapeutic Approach

8.1. Overview
- 8.1.1. Segment Share Analysis, By Therapeutic Approach, 2025 & 2033 (%)
- 8.1.2. Targeted Therapy
- 8.1.3. Chemotherapy
- 8.1.4. Stem Cell Transplant
- 8.1.5. Radiation Therapy
- 8.1.6. Immunotherapy
- 8.1.7. Others

9. Hematological Disorders Market - By Disease Type

9.1. Overview
- 9.1.1. Segment Share Analysis, By Disease Type, 2025 & 2033 (%)
- 9.1.2. Leukemia
- 9.1.3. Lymphoma
- 9.1.4. Multiple Myeloma
- 9.1.5. Anemia
- 9.1.6. Hemophilia & Other Bleeding Disorders
- 9.1.7. Sickle Cell Disease & Other Hemoglobinopathies
- 9.1.8. Thrombosis & Other Coagulation Disorders
- 9.1.9. Myelodysplastic & Myeloproliferative Disorders
- 9.1.10. Others

10. Hematological Disorders Market - By Disease Category

10.1. Overview
- 10.1.1. Segment Share Analysis, By Disease Category, 2025 & 2033 (%)
- 10.1.2. Malignant Hematological Disorders
- 10.1.3. Non-Malignant Hematological Disorders

11. Hematological Disorders Market- By Geography

11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
11.2. North America
- 11.2.1. Overview
- 11.2.2. Hematological Disorders Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.2.8. U.S.
  - 11.2.8.1. Overview
  - 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.2.8.3. U.S. Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.2.8.4. U.S. Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.2.8.5. U.S. Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.2.8.6. U.S. Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.2.9. Canada
  - 11.2.9.1. Overview
  - 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.2.9.3. Canada Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.2.9.4. Canada Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.2.9.5. Canada Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.2.9.6. Canada Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.3. Europe
- 11.3.1. Overview
- 11.3.2. Hematological Disorders Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.3.8. Germany
  - 11.3.8.1. Overview
  - 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.8.3. Germany Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.3.8.4. Germany Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.3.8.5. Germany Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.3.8.6. Germany Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.3.9. UK
  - 11.3.9.1. Overview
  - 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.9.3. UK Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.3.9.4. UK Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.3.9.5. UK Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.3.9.6. UK Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.3.10. France
  - 11.3.10.1. Overview
  - 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.10.3. France Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.3.10.4. France Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.3.10.5. France Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.3.10.6. France Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.3.11. Italy
  - 11.3.11.1. Overview
  - 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.11.3. Italy Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.3.11.4. Italy Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.3.11.5. Italy Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.3.11.6. Italy Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.3.12. Spain
  - 11.3.12.1. Overview
  - 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.12.3. Spain Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.3.12.4. Spain Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.3.12.5. Spain Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.3.12.6. Spain Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.3.13. The Netherlands
  - 11.3.13.1. Overview
  - 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.13.3. The Netherlands Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.3.13.4. The Netherlands Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.3.13.5. The Netherlands Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.3.13.6. The Netherlands Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.3.14. Sweden
  - 11.3.14.1. Overview
  - 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.14.3. Sweden Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.3.14.4. Sweden Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.3.14.5. Sweden Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.3.14.6. Sweden Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.3.15. Russia
  - 11.3.15.1. Overview
  - 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.15.3. Russia Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.3.15.4. Russia Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.3.15.5. Russia Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.3.15.6. Russia Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.3.16. Poland
  - 11.3.16.1. Overview
  - 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.16.3. Poland Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.3.16.4. Poland Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.3.16.5. Poland Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.3.16.6. Poland Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.3.17. Denmark
  - 11.3.17.1. Overview
  - 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.17.3. Poland Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.3.17.4. Denmark Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.3.17.5. Denmark Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.3.17.6. Denmark Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.3.18. Rest of Europe
  - 11.3.18.1. Overview
  - 11.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.18.3. Rest of the Europe Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.3.18.4. Rest of the Europe Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.3.18.5. Rest of the Europe Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.3.18.6. Rest of the Europe Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Hematological Disorders Key Manufacturers in Asia Pacific
- 11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.4.4. APAC Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
- 11.4.5. APAC Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
- 11.4.6. APAC Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
- 11.4.7. APAC Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.4.8. China
  - 11.4.8.1. Overview
  - 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.8.3. China Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.4.8.4. China Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.4.8.5. China Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.4.8.6. China Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.4.9. India
  - 11.4.9.1. Overview
  - 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.9.3. India Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.4.9.4. India Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.4.9.5. India Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.4.9.6. India Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.4.10. Japan
  - 11.4.10.1. Overview
  - 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.10.3. Japan Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.4.10.4. Japan Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.4.10.5. Japan Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.4.10.6. Japan Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.4.11. South Korea
  - 11.4.11.1. Overview
  - 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.11.3. South Korea Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.4.11.4. South Korea Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.4.11.5. South Korea Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.4.11.6. South Korea Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.4.12. Australia
  - 11.4.12.1. Overview
  - 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.12.3. Australia Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.4.12.4. Australia Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.4.12.5. Australia Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.4.12.6. Australia Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.4.13. Indonesia
  - 11.4.13.1. Overview
  - 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.13.3. Indonesia Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.4.13.4. Indonesia Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.4.13.5. Indonesia Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.4.13.6. Indonesia Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.4.14. Thailand
  - 11.4.14.1. Overview
  - 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.14.3. Thailand Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.4.14.4. Thailand Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.4.14.5. Thailand Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.4.14.6. Thailand Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.4.15. Philippines
  - 11.4.15.1. Overview
  - 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.15.3. Philippines Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.4.15.4. Philippines Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.4.15.5. Philippines Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.4.15.6. Philippines Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.4.16. Taiwan
  - 11.4.16.1. Overview
  - 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.16.3. Taiwan Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.4.16.4. Taiwan Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.4.16.5. Taiwan Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.4.16.6. Taiwan Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.4.17. Vietnam
  - 11.4.17.1. Overview
  - 11.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.17.3. Vietnam Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.4.17.4. Vietnam Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.4.17.5. Vietnam Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.4.17.6. Vietnam Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.4.18. Rest of APAC
  - 11.4.18.1. Overview
  - 11.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.18.3. Rest of APAC Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.4.18.4. Rest of APAC Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.4.18.5. Rest of APAC Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.4.18.6. Rest of APAC Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.5. Latin America (LATAM)
- 11.5.1. Overview
- 11.5.2. Hematological Disorders Key Manufacturers in Latin America
- 11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.5.4. LATAM Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
- 11.5.5. LATAM Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
- 11.5.6. LATAM Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
- 11.5.7. LATAM Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.5.8. Brazil
  - 11.5.8.1. Overview
  - 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.5.8.3. Brazil Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.5.8.4. Brazil Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.5.8.5. Brazil Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.5.8.6. Brazil Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.5.9. Mexico
  - 11.5.9.1. Overview
  - 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.5.9.3. Mexico Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.5.9.4. Mexico Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.5.9.5. Mexico Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.5.9.6. Mexico Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.5.10. Argentina
  - 11.5.10.1. Overview
  - 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.5.10.3. Argentina Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.5.10.4. Argentina Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.5.10.5. Argentina Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.5.10.6. Argentina Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.5.11. Colombia
  - 11.5.11.1. Overview
  - 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.5.11.3. Colombia Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.5.11.4. Colombia Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.5.11.5. Colombia Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.5.11.6. Colombia Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.5.12. Rest of LATAM
  - 11.5.12.1. Overview
  - 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.5.12.3. Rest of LATAM Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.5.12.4. Rest of LATAM Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.5.12.5. Rest of LATAM Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.5.12.6. Rest of LATAM Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.6. Middle East and Africa (MEA)
- 11.6.1. Overview
- 11.6.2. Hematological Disorders Key Manufacturers in Middle East and Africa
- 11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.6.4. MEA Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
- 11.6.5. MEA Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
- 11.6.6. MEA Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
- 11.6.7. MEA Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.6.8. Saudi Arabia
  - 11.6.8.1. Overview
  - 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.8.3. Saudi Arabia Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.6.8.4. Saudi Arabia Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.6.8.5. Saudi Arabia Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.6.8.6. Saudi Arabia Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.6.9. United Arab Emirates
  - 11.6.9.1. Overview
  - 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.9.3. United Arab Emirates Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.6.9.4. United Arab Emirates Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.6.9.5. United Arab Emirates Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.6.9.6. United Arab Emirates Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.6.10. Israel
  - 11.6.10.1. Overview
  - 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.10.3. Israel Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.6.10.4. Israel Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.6.10.5. Israel Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.6.10.6. Israel Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.6.11. Turkey
  - 11.6.11.1. Overview
  - 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.11.3. Turkey Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.6.11.4. Turkey Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.6.11.5. Turkey Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.6.11.6. Turkey Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.6.12. Algeria
  - 11.6.12.1. Overview
  - 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.12.3. Algeria Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.6.12.4. Algeria Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.6.12.5. Algeria Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.6.12.6. Algeria Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.6.13. Egypt
  - 11.6.13.1. Overview
  - 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.13.3. Egypt Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.6.13.4. Egypt Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.6.13.5. Egypt Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.6.13.6. Egypt Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.6.14. Iran
  - 11.6.14.1. Overview
  - 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.14.3. Iran Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.6.14.4. Iran Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.6.14.5. Iran Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.6.14.6. Iran Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.6.15. Qatar
  - 11.6.15.1. Overview
  - 11.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.15.3. Qatar Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.6.15.4. Qatar Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.6.15.5. Qatar Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.6.15.6. Qatar Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
- 11.6.16. Rest of MEA
  - 11.6.16.1. Overview
  - 11.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.16.3. Rest of MEA Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
  - 11.6.16.4. Rest of MEA Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
  - 11.6.16.5. Rest of MEA Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 11.6.16.6. Rest of MEA Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)

12. Key Vendor Analysis- Hematological Disorders Industry

12.1. Competitive Benchmarking
- 12.1.1. Competitive Dashboard
- 12.1.2. Competitive Positioning
12.2. Company Profiles
- 12.2.1. Abbott Laboratories
- 12.2.2. Amgen Inc.
- 12.2.3. Sanofi
- 12.2.4. Baxter International Inc.
- 12.2.5. Bayer AG
- 12.2.6. Bristol Myers Squibb
- 12.2.7. F. Hoffmann-La Roche Ltd.
- 12.2.8. Biogen Inc.
- 12.2.9. Novartis AG
- 12.2.10. Pfizer Inc.
- 12.2.11. GSK plc
- 12.2.12. Johnson & Johnson
- 12.2.13. Takeda Pharmaceutical Company Limited
- 12.2.14. Sysmex Corporation
- 12.2.15. Siemens Healthineers
- 12.2.16. AstraZeneca
- 12.2.17. AbbVie Inc.
- 12.2.18. CSL Behring
- 12.2.19. Novo Nordisk A/S
- 12.2.20. Vertex Pharmaceuticals
- 12.2.21. Sobi
- 12.2.22. Others

13. 360 Degree AnalystView

14. Appendix

14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격